Triple Antiretroviral Therapy Effectively Eliminates HIV Transmission from Mother to Child

Yıl 2016, Cilt: 2 Sayı: 4, 176 - 179, 01.10.2016

Sarma Nursani Lumbanraja

https://doi.org/10.5455/umj.20161215092116

Öz

Introduction: HIV transmission can be reduced by practicing appropriate prevention. Every centers have their own standardized regimens for antiretroviral therapy. The study aimed to determine HIV transmission after practicing standardized triple antiretroviral therapy adapted in Haji Adam Malik Hospital. Method: This is an cohort-analytic study conducted in Haji Adam Malik hospital. Medical records of HIV-positive mothers who did the antenatal care and delivered at Haji Adam Malik Hospital in 2009-2014 were collected. The standardized antiretroviral therapy adapted in Haji Adam Malik Hospital were applied. Follow up was done to all of the born children in order to determine HIV tranmission rate. Diagnosis of HIV in children under the age of 18 months were done by PCR Polymerase Chain Reaction . If the child has been aged ≥ 18 months, the method of diagnosis is Rapid Test. Results: Of the 60 infants examined, 11 infants aged

Anahtar Kelimeler

HIV, antiretroviral, transmission, pregnancy, fetal

Kaynakça

• 1.Drake AL, Wagner A, Richardson B & Stewart GJ. Incident HIV during Pregnancy and Postpartum and Risk of Motherto-Child HIV Transmission: A Systematic Review and MetaAnalysis. PloS 2014; 1-14.
• 2.WHO. Global HIV/AIDS response: epidemic update and health sector progress towards universal access.WHO,2011.
• 3.UNAIDS. Treatment 2015. UNAIDS:WHO,2015.
• 4.UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mother alive. UNAIDS, 2011.
• 5.Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010;362:2271-81.
• 6.Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
• 7. Baroncelli S, Tamburrini E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS2009;23:513-20.
• 8.Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol 10:217-229.
• 9.Ziakas, PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica, vol. 94, no. 7, pp. 998–1005, 2009.
• 10. Vrouenraets SM, Wit FW, Van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother. 2007 Apr; 8(6):851-71.
• 11. Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1- infected patients: three-year follow-up after switching therapy. HIV Clin Trials.2007;8:381–90.
• 12.Wooding AM. Antiviral efficacy of nine nucleoside reverse transciptase inhibitor against feline immunodeficiency virus in feline peripheral blood mononuclear cells.Available:https ://edoc.ub.uni-muenchen.de/18251/1/Wooding_Anita.pdf
• 13. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIVinfected patients. Clin Infect Dis 2008;46:1127-9.
• 14.WHO. Global update on HIV treatment 2013: result, impact, and opportunities. WHO, 2013: 1-126.
• 15.Cooper E, Charurat M, Mofenson L, et al: Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission. Acquir Immune Defic Syndr. 2002,29:484-494.
• 16.WHO,UNAIDS and UNICEF:Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, 2005, 2006, 2007, 2008, 2009, 2010,WHO, UNAIDS, UNICEF. 2009, Available at http://data. unaids.org/ pub/Report/2009/20090930/tuapr2009_en.pdf